Effect of Antidepressants on White Matter Structure

Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal

Status and phase: Unknown; Phase 4

Conditions: Major Depression

Treatments: Drug: Desvenlafaxine

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01492621

DTI

Details and patient eligibility

About

Subjects with major depression will be evaluated and intensively characterized through questionnaires, computerized cognitive evaluation and laboratory investigations. Magnetic resonance imaging will be used to document baseline white matter structure. subjects will then receive desvenlafaxine which will be adjusted as clinically indicated. After 16 weeks the evaluations will be repeated.

Full description

40 subjects will be included in the study. Diagnosis will be confirmed by MINI. Participants will be characterised using questionnaires, pain threshold, cognition, facial expression recording and MRI. Desvenlafaxine will be initiated at 50mg AM. At week 8 Desvenlafaxine may be increased to 100mg as clinically indicated. Measures will be repeated at the end of the study.

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Major depression
• Age 18 to 55
• Hamilton grater or equal to 20

Exclusion criteria

• Major neurologic disorder
• Major cardiovascular disorder
• Unstable medical condition
• Significant psychiatric co-morbidity
• Current substance dependance
• Pregnancy or lactation -Treatment resistance as defined by nonresponse to 2 or more antidepressant treatments (adequate dose and duration) -

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)